2020
Age-, sex- and disease subtype–related foetal growth differentials in childhood acute myeloid leukaemia risk: A Childhood Leukemia International Consortium analysis
Karalexi MA, Dessypris N, Ma X, Spector LG, Marcotte E, Clavel J, Pombo-de-Oliveira MS, Heck JE, Roman E, Mueller BA, Hansen J, Auvinen A, Lee PC, Schüz J, Magnani C, Mora AM, Dockerty JD, Scheurer ME, Wang R, Bonaventure A, Kane E, Doody DR, Group N, Baka M, Moschovi M, Polychronopoulou S, Kourti M, Hatzipantelis E, Pelagiadis I, Dana H, Kantzanou M, Tzanoudaki M, Anastasiou T, Grenzelia M, Gavriilaki E, Sakellari I, Anagnostopoulos A, Kitra V, Paisiou A, Bouka E, Group F, Nikkilä A, Lohi O, Erdmann F, Kang A, Metayer C, Milne E, Petridou E. Age-, sex- and disease subtype–related foetal growth differentials in childhood acute myeloid leukaemia risk: A Childhood Leukemia International Consortium analysis. European Journal Of Cancer 2020, 130: 1-11. PMID: 32163883, DOI: 10.1016/j.ejca.2020.01.018.Peer-Reviewed Original ResearchConceptsAcute myeloid leukemiaChildhood Leukemia International ConsortiumGestational ageFoetal growthInfant boyAcute myeloid leukemia riskMyeloid leukemia riskNewborn Growth ConsortiumRare childhood cancerBirth lengthGrowth markersChildhood cancerAML subtypesAML casesMyeloid leukemiaLeukemia riskNull associationDisease subtypesInternational FetalAgeMore studiesConsortium analysisLeukemiaSexBoysVenetoclax as monotherapy and in combination with hypomethylating agents or low dose cytarabine in relapsed and treatment refractory acute myeloid leukemia: a systematic review and meta-analysis
Bewersdorf JP, Giri S, Wang R, Williams RT, Tallman MS, Zeidan AM, Stahl M. Venetoclax as monotherapy and in combination with hypomethylating agents or low dose cytarabine in relapsed and treatment refractory acute myeloid leukemia: a systematic review and meta-analysis. Haematologica 2020, 105: 2659-2663. PMID: 33131256, PMCID: PMC7604631, DOI: 10.3324/haematol.2019.242826.Peer-Reviewed Original Research
2019
Increased neonatal level of arginase 2 in cases of childhood acute lymphoblastic leukemia implicates immunosuppression in the etiology
Nielsen AB, Zhou M, de Smith AJ, Wang R, McCoy L, Hansen H, Morimoto L, Grønbæk K, Johansen C, Kogan SC, Metayer C, Bracci PM, Ma X, Wiemels JL. Increased neonatal level of arginase 2 in cases of childhood acute lymphoblastic leukemia implicates immunosuppression in the etiology. Haematologica 2019, 104: e514-e516. PMID: 30923090, PMCID: PMC6821599, DOI: 10.3324/haematol.2019.216465.Peer-Reviewed Original Research
2017
32 Hypomethylating Agent Therapy use and Survival in Older Patients with Chronic Myelomonocytic Leukemia in USA: A Large Population-Based Study
Zeidan A, Hu X, Long J, Wang R, Ma X, Podoltsev N, Huntington S, Gore S, Davidoff A. 32 Hypomethylating Agent Therapy use and Survival in Older Patients with Chronic Myelomonocytic Leukemia in USA: A Large Population-Based Study. Leukemia Research 2017, 55: s20-s21. DOI: 10.1016/s0145-2126(17)30145-5.Peer-Reviewed Original Research
2016
Hypomethylating Agent Therapy and Survival Among Older Patients with Chronic Myelomonocytic Leukemia in the United States: A Large Population-Based Study
Zeidan A, Hu X, Long J, Wang R, Huntington S, Podoltsev N, Gore S, Ma X, Davidoff A. Hypomethylating Agent Therapy and Survival Among Older Patients with Chronic Myelomonocytic Leukemia in the United States: A Large Population-Based Study. Blood 2016, 128: 394. DOI: 10.1182/blood.v128.22.394.394.Peer-Reviewed Original ResearchChronic myelomonocytic leukemiaMyelodysplastic syndromeSurvival benefitHigh-risk myelodysplastic syndromeDemonstrated survival benefitRetrospective cohort studyRisk myelodysplastic syndromesUse of HMAsAgent azacitidineLack of evidenceCohort studyClinical entityMyelomonocytic leukemiaBiologic evidenceOlder adultsAzacitidineUnited StatesHMAsEnd resultPatientsSyndromeLeukemiaDecitabineEpidemiology
2009
Diet, Lifestyle, and Acute Myeloid Leukemia in the NIH–AARP Cohort
Ma X, Park Y, Mayne ST, Wang R, Sinha R, Hollenbeck AR, Schatzkin A, Cross AJ. Diet, Lifestyle, and Acute Myeloid Leukemia in the NIH–AARP Cohort. American Journal Of Epidemiology 2009, 171: 312-322. PMID: 20042434, PMCID: PMC2842202, DOI: 10.1093/aje/kwp371.Peer-Reviewed Original ResearchConceptsAcute myeloid leukemiaPack/dayMyeloid leukemiaHazard ratioMeat intakeNIH-AARP DietLarge prospective studiesMultivariate Cox modelHigh meat intakeMeat cooking methodsNIH-AARP cohortCurrent smokersFormer smokersIncident casesProspective studyUS cohortVegetable intakeDoneness levelRisk factorsHigh riskCox modelHealth StudyLeukemiaSmokersConfidence intervals
2007
Family history of hematopoietic and non-hematopoietic malignancies and risk of non-Hodgkin lymphoma
Zhang Y, Wang R, Holford TR, Leaderer B, Zahm SH, Boyle P, Zhu Y, Qin Q, Zheng T. Family history of hematopoietic and non-hematopoietic malignancies and risk of non-Hodgkin lymphoma. Cancer Causes & Control 2007, 18: 351-359. PMID: 17206533, DOI: 10.1007/s10552-006-0088-5.Peer-Reviewed Original ResearchConceptsRisk of NHLNon-Hodgkin lymphomaFirst-degree relativesNon-hematopoietic malignanciesFamily historyNHL subtypesPopulation-based case-control studyUnconditional logistic regressionCase-control studyFamily cancer historyNHL overallIncident casesCancer historyConclusionsThe riskConnecticut womenMalignancyLymphomaLogistic regressionHematopoietic malignanciesLeukemiaWomenRiskSubtypesSiblingsCervix